Last updated: February 23, 2026
What is the Pharmaceutical Product?
NDC 57664-0688 corresponds to Syntocinon (oxytocin) injection, a synthetic hormone used to induce labor, control postpartum bleeding, and manage incomplete pregnancy. It is widely employed in obstetrics and gynecology.
Market Overview
Market Size and Growth
The global obstetric drugs market was valued at approximately $4.3 billion in 2021, projected to grow at a compound annual growth rate (CAGR) of 5.2% from 2022 to 2028 (Fortune Business Insights). Oxytocin remains a core component due to its established safety profile and cost-effectiveness.
Key Regional Markets
| Region |
Estimated Market Share |
Projected Growth Rate (2022-2028) |
| North America |
38% |
4.8% |
| Europe |
25% |
5.0% |
| Asia-Pacific |
22% |
6.2% |
| Rest of World |
15% |
5.4% |
The Asia-Pacific region exhibits the highest growth driven by expanding healthcare infrastructure and neonatal care efforts, especially in China and India.
Competitive Landscape
Market players include:
- Pfizer Inc.
- Ferring Pharmaceuticals
- Novartis AG
- Teva Pharmaceutical Industries
- Labsynth S.p.A
Pfizer holds a significant share due to its market penetration and extensive distribution channels.
Regulatory Environment
Regulations for oxytocin are strict in developed countries, requiring approval from agencies like the FDA (U.S.), EMA (Europe), and PMDA (Japan). The product is generally approved as a prescription drug with established manufacturing standards (GMP).
Price Analysis
Current Pricing
| Region |
Average Price per 10mL Vial (USD) |
Notes |
| United States |
$8.50 |
Based on wholesale acquisition costs (WAC) |
| Europe |
€6.50 (~$7.20) |
Around average from European health systems |
| India |
$2.50 |
Retail prices, local generic availability |
Prices are influenced by manufacturing costs, regulatory costs, and market competition. The U.S. prices are higher due to distribution and regulatory overheads.
Price Trends
- Generic versions have driven prices down approximately 10-15% annually in most regions.
- Certain markets with limited competition, such as China and Russia, maintain higher prices (~$9.00–$10.00 per vial).
- New formulation approvals and patent disputes do not significantly influence oxytocin prices, as most formulations are off-patent.
Future Price Projections
| Year |
Estimated Price per 10mL Vial (USD) |
Assumptions |
| 2023 |
$8.50 |
Current market levels maintained |
| 2025 |
$7.80 |
Increased generic penetration, manufacturing efficiencies |
| 2028 |
$7.20 |
Continued price compression, market saturation |
Price reductions are expected as more generics enter emerging markets and manufacturing technology improves. However, in some regions, prices may stabilize due to regulatory or supply chain constraints.
Regulatory and Patent Outlook
Oxytocin's patent expired in various markets over a decade ago, leading to a proliferation of generics. No recent patent filings or patent extensions for NDC 57664-0688 have been noted. Regulatory approval processes for generics in key markets are well-established, enabling rapid market entry.
Market Entry Considerations
- Manufacturing compliance with local GMP standards.
- Competitive pricing strategies, emphasizing cost leadership.
- Potential for biosimilar or formulation innovations in regional markets.
- Importance of local distribution networks for wide availability.
Key Takeaways
- NDC 57664-0688 (oxytocin injection) dominates a stable, mature market with steady growth in neonatal care needs.
- The global market is set to grow at 5.2% CAGR, with emerging markets leading the expansion.
- Prices are declining due to generic competition, averaging around $8.50 per 10mL vial in the U.S., with projections to slightly decrease.
- The absence of current patent protections signals low barriers to generic entry, further pressuring prices.
- Regulatory adherence and competitive pricing remain critical for market success.
FAQs
1. What factors influence the pricing of oxytocin injections worldwide?
Manufacturing costs, regulatory requirements, competition from generics, supply chain logistics, and regional health system budgets.
2. Are there emerging alternatives to oxytocin for labor induction?
Yes. Alternatives include misoprostol and ergometrine, but oxytocin remains the gold standard due to established efficacy and safety.
3. How does regulatory approval impact market dynamics?
Strict regulatory standards slow new entries but facilitate generics through streamlined approval processes once patents expire.
4. What is the outlook for innovation in oxytocin formulations?
Limited innovation; focus remains on manufacturing efficiencies and supply chain optimization rather than new formulations.
5. How do patent expirations affect market competition?
Patent expirations open the market to generics, increasing competition and driving prices downward.
References
[1] Fortune Business Insights. (2022). Global obstetric drugs market size, share & industry analysis.
[2] IQVIA. (2021). Global pharmaceutical market reports.
[3] FDA. (2022). Approved drug labeling for oxytocin.
[4] EMA. (2022). European public assessment reports for obstetric drugs.
